UBS Group Increases Danaher (NYSE:DHR) Price Target to $165.00

Danaher (NYSE:DHR) had its target price hoisted by UBS Group from $158.00 to $165.00 in a report released on Monday, BenzingaRatingsTable reports. The firm presently has a “buy” rating on the conglomerate’s stock. UBS Group’s target price would indicate a potential upside of 12.48% from the stock’s previous close.

A number of other research firms have also recently weighed in on DHR. ValuEngine cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Needham & Company LLC dropped their target price on shares of Danaher from $155.00 to $152.00 and set a “buy” rating on the stock in a research report on Monday, October 28th. Stifel Nicolaus reissued a “hold” rating and set a $150.00 target price on shares of Danaher in a research note on Thursday, November 14th. Wolfe Research set a $154.00 price target on shares of Danaher and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $151.00 price target on shares of Danaher in a research note on Monday, October 14th. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $147.53.

Danaher stock opened at $146.69 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.43 and a quick ratio of 3.09. The stock has a market capitalization of $104.85 billion, a PE ratio of 32.45, a price-to-earnings-growth ratio of 2.45 and a beta of 0.92. The business has a 50 day simple moving average of $139.57 and a 200-day simple moving average of $139.66. Danaher has a 12 month low of $94.59 and a 12 month high of $147.33.

Danaher (NYSE:DHR) last announced its earnings results on Thursday, October 24th. The conglomerate reported $1.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.15 by $0.01. Danaher had a return on equity of 11.42% and a net margin of 12.13%. The firm had revenue of $5.04 billion for the quarter, compared to analyst estimates of $5.02 billion. During the same quarter last year, the firm posted $1.10 EPS. The business’s revenue was up 3.8% on a year-over-year basis. On average, equities research analysts anticipate that Danaher will post 4.76 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Nuveen Asset Management LLC raised its position in shares of Danaher by 10,853.5% in the second quarter. Nuveen Asset Management LLC now owns 3,664,924 shares of the conglomerate’s stock valued at $523,790,000 after buying an additional 3,631,465 shares during the last quarter. Janus Henderson Group PLC boosted its position in Danaher by 274.8% during the second quarter. Janus Henderson Group PLC now owns 2,858,029 shares of the conglomerate’s stock worth $408,466,000 after acquiring an additional 2,095,396 shares during the last quarter. Jennison Associates LLC boosted its position in Danaher by 38.4% during the second quarter. Jennison Associates LLC now owns 5,135,358 shares of the conglomerate’s stock worth $733,945,000 after acquiring an additional 1,424,328 shares during the last quarter. Sustainable Growth Advisers LP acquired a new position in Danaher during the second quarter worth about $124,387,000. Finally, Vanguard Group Inc. grew its stake in Danaher by 1.4% during the 2nd quarter. Vanguard Group Inc. now owns 48,262,218 shares of the conglomerate’s stock valued at $6,897,635,000 after acquiring an additional 686,421 shares in the last quarter. 78.10% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

See Also: What are different types of coverage ratios?

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.